ImmunoBrain Checkpoint, Inc. is a biopharmaceutical company focused on developing a pipeline of novel disease-modifying immunotherapies for neurological disorders by targeting immune checkpoint pathways. IBC’s novel approach for treatment of neurodegeneration is based on years of innovative, cutting edge scientific discoveries made by Prof. Michal Schwartz (Weizmann Institute of Science, Israel). 

 

Our lead programs are being developed for the treatment of Alzheimer's disease, employing a novel approach of blocking the PD-1/PD-L1 immune checkpoint pathway.

Harnessing the immune system for brain repair

*** Our Website Coming Soon ***